Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

Synopsis

At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies. More information can be found under 'Post-authorisation safety studies'.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.